Subjects -> MEDICAL SCIENCES (Total: 8789 journals)
    - ALLERGOLOGY AND IMMUNOLOGY (223 journals)
    - ANAESTHESIOLOGY (121 journals)
    - CARDIOVASCULAR DISEASES (348 journals)
    - CHIROPRACTIC, HOMEOPATHY, OSTEOPATHY (21 journals)
    - COMMUNICABLE DISEASES, EPIDEMIOLOGY (234 journals)
    - DENTISTRY (291 journals)
    - DERMATOLOGY AND VENEREOLOGY (166 journals)
    - EMERGENCY AND INTENSIVE CRITICAL CARE (126 journals)
    - ENDOCRINOLOGY (151 journals)
    - FORENSIC SCIENCES (44 journals)
    - GASTROENTEROLOGY AND HEPATOLOGY (191 journals)
    - GERONTOLOGY AND GERIATRICS (138 journals)
    - HEMATOLOGY (159 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (179 journals)
    - LABORATORY AND EXPERIMENTAL MEDICINE (99 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2452 journals)
    - NURSES AND NURSING (372 journals)
    - OBSTETRICS AND GYNECOLOGY (211 journals)
    - ONCOLOGY (393 journals)
    - OPHTHALMOLOGY AND OPTOMETRY (141 journals)
    - ORTHOPEDICS AND TRAUMATOLOGY (172 journals)
    - OTORHINOLARYNGOLOGY (83 journals)
    - PATHOLOGY (100 journals)
    - PEDIATRICS (277 journals)
    - PHYSICAL MEDICINE AND REHABILITATION (159 journals)
    - PSYCHIATRY AND NEUROLOGY (840 journals)
    - RADIOLOGY AND NUCLEAR MEDICINE (195 journals)
    - RESPIRATORY DISEASES (108 journals)
    - RHEUMATOLOGY (79 journals)
    - SPORTS MEDICINE (83 journals)
    - SURGERY (412 journals)
    - UROLOGY, NEPHROLOGY AND ANDROLOGY (159 journals)

UROLOGY, NEPHROLOGY AND ANDROLOGY (159 journals)                     

Showing 1 - 159 of 159 Journals sorted alphabetically
Acta Urológica Portuguesa     Open Access   (Followers: 1)
Actas Urológicas Españolas     Full-text available via subscription   (Followers: 3)
Actas Urológicas Españolas (English Edition)     Full-text available via subscription   (Followers: 1)
Advances in Chronic Kidney Disease     Full-text available via subscription   (Followers: 11)
Advances in Urology     Open Access   (Followers: 13)
African Journal of Nephrology     Open Access  
African Journal of Urology     Open Access   (Followers: 7)
AJP Renal Physiology     Hybrid Journal   (Followers: 8)
Aktuelle Urologie     Hybrid Journal   (Followers: 4)
American Journal of Kidney Diseases     Hybrid Journal   (Followers: 43)
American Journal of Men's Health     Open Access   (Followers: 9)
American Journal of Nephrology     Full-text available via subscription   (Followers: 38)
Andrologia     Hybrid Journal   (Followers: 2)
Andrology     Hybrid Journal   (Followers: 4)
Andrology & Gynecology : Current Research     Hybrid Journal   (Followers: 4)
Andrology and Genital Surgery     Open Access   (Followers: 7)
Andrology-Open Access     Open Access  
Annales d'Urologie     Full-text available via subscription  
Arab Journal of Nephrology and Transplantation     Open Access   (Followers: 1)
Arab Journal of Urology     Open Access   (Followers: 7)
Archives of Clinical Nephrology     Open Access   (Followers: 2)
Archivio Italiano di Urologia e Andrologia     Open Access   (Followers: 1)
Archivos Españoles de Urología     Open Access  
Asian Journal of Andrology     Open Access   (Followers: 1)
Asian Journal of Urology     Open Access   (Followers: 3)
Bangladesh Journal of Urology     Open Access   (Followers: 5)
BANTAO Journal     Open Access  
Basic and Clinical Andrology     Open Access  
BJU International     Hybrid Journal   (Followers: 34)
BJUI Compass     Open Access   (Followers: 2)
BMC Nephrology     Open Access   (Followers: 11)
BMC Urology     Open Access   (Followers: 14)
Canadian Journal of Kidney Health and Disease     Open Access   (Followers: 8)
Canadian Urological Association Journal     Open Access   (Followers: 2)
Cancer Urology     Open Access   (Followers: 2)
Cardiorenal Medicine     Full-text available via subscription   (Followers: 1)
Case Reports in Nephrology     Open Access   (Followers: 5)
Case Reports in Nephrology and Dialysis     Open Access   (Followers: 9)
Case Reports in Urology     Open Access   (Followers: 12)
Clinical and Experimental Nephrology     Hybrid Journal   (Followers: 4)
Clinical Journal of the American Society of Nephrology     Full-text available via subscription   (Followers: 22)
Clinical Kidney Journal     Open Access   (Followers: 4)
Clinical Medicine Insights : Urology     Open Access   (Followers: 3)
Clinical Nephrology     Full-text available via subscription   (Followers: 8)
Clinical Nephrology and Urology Science     Open Access   (Followers: 6)
Clinical Queries: Nephrology     Hybrid Journal   (Followers: 1)
Cuadernos de Cirugía     Open Access   (Followers: 3)
Current Opinion in Nephrology & Hypertension     Hybrid Journal   (Followers: 10)
Current Opinion in Urology     Hybrid Journal   (Followers: 12)
Current Urology     Open Access   (Followers: 10)
Current Urology Reports     Hybrid Journal   (Followers: 5)
Der Nephrologe     Hybrid Journal  
Der Urologe     Hybrid Journal   (Followers: 1)
Diabetic Nephropathy     Open Access   (Followers: 1)
EMC - Urología     Full-text available via subscription  
Enfermería Nefrológica     Open Access   (Followers: 1)
European Urology     Full-text available via subscription   (Followers: 33)
European Urology Focus     Hybrid Journal   (Followers: 5)
European Urology Oncology     Hybrid Journal   (Followers: 1)
European Urology Open Science     Open Access   (Followers: 10)
Forum Nefrologiczne     Full-text available via subscription  
Geriatric Nephrology and Urology     Hybrid Journal   (Followers: 7)
Giornale di Clinica Nefrologica e Dialisi     Open Access  
Herald Urology     Open Access   (Followers: 2)
Hong Kong Journal of Nephrology     Open Access   (Followers: 3)
Human Andrology     Partially Free   (Followers: 2)
IJU Case Reports     Open Access  
Indian Journal of Nephrology     Open Access   (Followers: 2)
Indian Journal of Urology     Open Access   (Followers: 5)
International Brazilian Journal of Urology     Open Access   (Followers: 5)
International Journal of Nephrology     Open Access   (Followers: 2)
International Journal of Nephrology and Renovascular Disease     Open Access   (Followers: 2)
International Journal of Urology     Hybrid Journal   (Followers: 12)
International Urology and Nephrology     Hybrid Journal   (Followers: 7)
Jornal Brasileiro de Nefrologia     Open Access  
Journal für Urologie und Urogynäkologie/Österreich     Hybrid Journal  
Journal of Clinical Nephrology     Open Access   (Followers: 2)
Journal of Clinical Urology     Hybrid Journal   (Followers: 14)
Journal of Endoluminal Endourology     Open Access  
Journal of Endourology     Hybrid Journal   (Followers: 2)
Journal of Endourology Case Reports     Hybrid Journal  
Journal of Genital System & Disorders     Hybrid Journal   (Followers: 3)
Journal of Integrative Nephrology and Andrology     Open Access   (Followers: 2)
Journal of Kidney Cancer and VHL     Open Access  
Journal of Lower Genital Tract Disease     Hybrid Journal  
Journal of Nephrology     Hybrid Journal   (Followers: 4)
Journal of Nephrology Research     Open Access   (Followers: 3)
Journal of Pediatric Nephrology     Open Access   (Followers: 5)
Journal of Renal Care     Hybrid Journal   (Followers: 8)
Journal of Renal Nursing     Full-text available via subscription   (Followers: 12)
Journal of Renal Nutrition     Hybrid Journal   (Followers: 28)
Journal of Renal Nutrition and Metabolism     Open Access   (Followers: 1)
Journal of the American Society of Nephrology     Full-text available via subscription   (Followers: 31)
Journal of The Egyptian Society of Nephrology and Transplantation     Open Access  
Journal of Translational Neurosciences     Open Access  
Journal of Urology     Full-text available via subscription   (Followers: 46)
Journal of Urology & Nephrology     Open Access   (Followers: 2)
Kidney Disease and Transplantation     Open Access   (Followers: 4)
Kidney Diseases     Open Access   (Followers: 3)
Kidney International     Hybrid Journal   (Followers: 47)
Kidney International Reports     Open Access   (Followers: 3)
Kidney Medicine     Open Access  
Kidney Research Journal     Open Access   (Followers: 6)
Kidneys (Počki)     Open Access   (Followers: 1)
Nature Reviews Nephrology     Full-text available via subscription   (Followers: 23)
Nature Reviews Urology     Full-text available via subscription   (Followers: 13)
Nefrología (English Edition)     Open Access  
Nefrología (Madrid)     Open Access  
Nephro-Urology Monthly     Open Access   (Followers: 1)
Nephrology     Hybrid Journal   (Followers: 13)
Nephrology Dialysis Transplantation     Hybrid Journal   (Followers: 27)
Nephron     Hybrid Journal   (Followers: 4)
Nephron Clinical Practice     Full-text available via subscription   (Followers: 4)
Nephron Experimental Nephrology     Full-text available via subscription   (Followers: 4)
Nephron Extra     Open Access   (Followers: 1)
Nephron Physiology     Full-text available via subscription   (Followers: 4)
Neurourology and Urodynamics     Hybrid Journal   (Followers: 1)
OA Nephrology     Open Access   (Followers: 2)
Open Access Journal of Urology     Open Access   (Followers: 6)
Open Journal of Nephrology     Open Access   (Followers: 5)
Open Journal of Urology     Open Access   (Followers: 6)
Open Urology & Nephrology Journal     Open Access  
Pediatric Urology Case Reports     Open Access   (Followers: 7)
Portuguese Journal of Nephrology & Hypertension     Open Access   (Followers: 1)
Progrès en Urologie     Full-text available via subscription  
Progrès en Urologie - FMC     Full-text available via subscription  
Prostate Cancer and Prostatic Diseases     Hybrid Journal   (Followers: 6)
Renal Failure     Open Access   (Followers: 12)
Renal Replacement Therapy     Open Access   (Followers: 4)
Research and Reports in Urology     Open Access   (Followers: 4)
Revista de Nefrología, Diálisis y Trasplante     Open Access   (Followers: 1)
Revista Mexicana de Urología     Open Access   (Followers: 1)
Revista Urologia Colombiana     Open Access  
Saudi Journal of Kidney Diseases and Transplantation     Open Access   (Followers: 2)
Scandinavian Journal of Urology     Hybrid Journal   (Followers: 7)
Seminars in Nephrology     Hybrid Journal   (Followers: 11)
The Prostate     Hybrid Journal   (Followers: 8)
Therapeutic Advances in Urology     Open Access   (Followers: 4)
Trends in Urology & Men's Health     Partially Free   (Followers: 1)
Ukrainian Journal of Nephrology and Dialysis     Open Access   (Followers: 1)
Uro-News     Hybrid Journal   (Followers: 1)
Urolithiasis     Hybrid Journal   (Followers: 2)
Urologia Internationalis     Full-text available via subscription   (Followers: 2)
Urologia Journal     Hybrid Journal  
Urologic Clinics of North America     Full-text available via subscription   (Followers: 4)
Urologic Nursing     Full-text available via subscription   (Followers: 4)
Urologic Radiology     Hybrid Journal  
Urological Science     Open Access  
Urologicheskie Vedomosti     Open Access  
Urologie in der Praxis     Hybrid Journal  
Urologie Scan     Hybrid Journal  
Urology     Hybrid Journal   (Followers: 33)
Urology Annals     Open Access   (Followers: 4)
Urology Case Reports     Open Access   (Followers: 3)
Urology Practice     Full-text available via subscription   (Followers: 2)
Urology Times     Free   (Followers: 3)
Urology Video Journal     Open Access   (Followers: 1)
World Journal of Nephrology and Urology     Open Access   (Followers: 15)
World Journal of Urology     Hybrid Journal   (Followers: 11)

           

Similar Journals
Journal Cover
Nephrology Dialysis Transplantation
Journal Prestige (SJR): 2.142
Citation Impact (citeScore): 4
Number of Followers: 27  
 
  Hybrid Journal Hybrid journal (It can contain Open Access articles)
ISSN (Print) 0931-0509 - ISSN (Online) 1460-2385
Published by Oxford University Press Homepage  [414 journals]
  • Living well with kidney disease by patient and care partner empowerment:
           kidney health for everyone everywhere
    • Authors: Kalantar-Zadeh K; Li P, Tantisattamo E, et al.
      Pages: 197 - 201
      PubDate: Mon, 25 Jan 2021 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa336
      Issue No: Vol. 36, No. 2 (2021)
       
  • Renal transplant outcomes in amyloidosis
    • Authors: Law S; Cohen O, Lachmann H, et al.
      Pages: 355 - 365
      Abstract: BackgroundOutcomes after renal transplantation have traditionally been poor in systemic amyloid A (AA) amyloidosis and systemic light chain (AL) amyloidosis, with high mortality and frequent recurrent disease. We sought to compare outcomes with matched transplant recipients with autosomal dominant polycystic kidney disease (ADPKD) and diabetic nephropathy (DN), and identify factors predictive of outcomes.MethodsWe performed a retrospective cohort study of 51 systemic AL and 48 systemic AA amyloidosis patients undergoing renal transplantation. Matched groups were generated by propensity score matching. Patient and death-censored allograft survival were compared via Kaplan–Meier survival analyses, and assessment of clinicopathological features predicting outcomes via Cox proportional hazard analyses.ResultsOne-, 5- and 10-year death-censored unadjusted graft survival was, respectively, 94, 91 and 78% for AA amyloidosis, and 98, 93 and 93% for AL amyloidosis; median patient survival was 13.1 and 7.9 years, respectively. Patient survival in AL and AA amyloidosis was comparable to DN, but poorer than ADPKD [hazard ratio (HR) = 3.12 and 3.09, respectively; P < 0.001]. Death-censored allograft survival was comparable between all groups. In AL amyloidosis, mortality was predicted by interventricular septum at end diastole (IVSd) thickness >12 mm (HR = 26.58; P = 0.03), while survival was predicted by haematologic response (very good partial or complete response; HR = 0.07; P = 0.018). In AA amyloidosis, recurrent amyloid was associated with elevated serum amyloid A concentration but not with outcomes.ConclusionsRenal transplantation outcomes for selected patients with AA and AL amyloidosis are comparable to those with DN. In AL amyloidosis, IVSd thickness and achievement of deep haematologic response pre-transplant profoundly impact patient survival.
      PubDate: Wed, 13 Jan 2021 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa293
      Issue No: Vol. 36, No. 2 (2021)
       
  • Bone biopsy in chronic kidney disease: still neglected and in need of
           revitalization
    • Authors: Mazzaferro S; Pasquali M.
      Pages: 202 - 204
      Abstract: Renal osteodystrophy (ROD) is now included in the larger chronic kidney disease–mineral bone disorder (CKD-MBD) with evidence of a specific contribution to increased mortality in renal diseases. Bone biopsy is universally recognized as the gold standard diagnostic test for ROD, but due to limited diffusion, Kidney Disease: Improving Global Outcome (KDIGO) guidelines do not recommend it widely. The now better-appreciated endocrine role of bone and the intriguing relationship between osteoporosis and ROD in chronic renal failure warrants a definite appreciation of the pathomechanisms involved in these diseases to decide the best therapy. In particular, antiresorptive therapies now available for osteoporosis should be better evaluated in renal patients with bone biopsies. For this reason, the paper by Novel-Catin et al. [1] suggesting the use of a small needle to perform bone biopsies deserves attention, because it could enable the increased use of bone biopsies in CKD.
      PubDate: Sat, 14 Nov 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa269
      Issue No: Vol. 36, No. 2 (2020)
       
  • Long- or short-acting erythropoiesis-stimulating agents: take no shortcuts
           in their evaluation
    • Authors: Hodson E; Strippoli G.
      Pages: 205 - 207
      Abstract: The main cause of anaemia in chronic kidney disease (CKD) is decreased production of erythropoietin in the kidney exacerbated by concurrent relative iron deficiency [1]. Before recombinant human erythropoietin became available, anaemia in CKD was managed with blood transfusions and iron supplements. The efficacy of erythropoiesis-stimulating agents (ESAs) was first demonstrated in dialysis patients in 1986 [2] and was subsequently assessed in randomized controlled trials (RCTs). Evidence from RCTs has been summarized extensively in systematic reviews [3–7]. A systematic review of 19 RCTs in 993 participants with anaemia and CKD who did not require dialysis concluded that ESAs (epoetin alfa or epoetin beta) compared with placebo or no treatment improved anaemia and reduced the need for blood transfusion [3]. Initially, clinicians aimed for partial correction of anaemia with ESA treatment [8], but practice gradually shifted towards full correction of anaemia based on the belief that normalization of haemoglobin (Hb)/haematocrit would be of cardiovascular benefit. This belief was supported by a series of observational studies that found an association of higher Hb/haematocrit levels with reduced risk of death and improved cardiovascular outcomes [9, 10]. However, when this observational hypothesis was trialled in the Normal Hematocrit Study in a high cardiac risk haemodialysis population (n = 1233), the trial had to be prematurely interrupted because of the evidence of increased risk of death with normal HB levels (14 mg/dL) [8]. Whether treating anaemia in people with type 2 diabetes who were not on dialysis was better than placebo was then tested in a large RCT of 4038 patients [11]. This trial found that participants treated with darbepoetin to achieve a mean Hb of 13.0 g/dL compared with a mean Hb of 10.6 g/L showed no differences in the two primary outcomes [composite outcomes of death or a cardiovascular event and death or end-stage renal disease (ESRD)], but there was an increased risk of stroke. In summary, a large systematic review of 27 RCTs (10 452 participants) concluded that the risks of fatal and non-fatal stroke, vascular access thrombosis and hypertension were increased with higher Hb targets (median 13 mg/dL) compared with lower targets (median 10.1 mg/dL) in both dialysis and non-dialysis CKD patients [12].
      PubDate: Wed, 24 Jun 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa118
      Issue No: Vol. 36, No. 2 (2020)
       
  • Acute kidney injury in patients with COVID-19: an update on the
           pathophysiology
    • Authors: Izzedine H; Jhaveri K.
      Pages: 224 - 226
      Abstract: Acute kidney injury (AKI) is common in critically ill patients with coronavirus disease 2019 (COVID-19), affecting ∼20–40% of patients admitted to intensive care, and is considered as a marker of disease severity and a negative prognostic factor for survival [1,2].
      PubDate: Sat, 05 Sep 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa184
      Issue No: Vol. 36, No. 2 (2020)
       
  • Plasma exchange in ANCA-associated vasculitis: the pro position
    • Authors: Kronbichler A; Shin J, Wang C, et al.
      Pages: 227 - 231
      Abstract: Plasma exchange (PLEX) is capable of removing significant amounts of circulating antibodies. In anti-neutrophil cytoplasmic antibody-associated vasculitis, PLEX was reserved for patients with severe presentation forms such as rapidly progressive glomerulonephritis and pulmonary haemorrhage. The Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis (PEXIVAS) trial included all comers with a glomerular filtration rate <50 mL/min/1.73 m2 and thus aimed to answer the question of whether PLEX is an option for patients with no relevant kidney function impairment or not. PEXIVAS revealed that after a follow-up of almost 3 years, routine administration of PLEX does not provide an additional benefit to reduce the rate of a composite comprising end-stage kidney disease or death. In the absence of histological parameters, it is tempting to speculate whether PLEX is effective or not in those with a potential for renal recovery. A subset of patients presented with alveolar haemorrhage, and there was a trend towards a better outcome of such cases receiving PLEX. This would be in line with observational studies reporting a recovery of alveolar haemorrhage following extracorporeal treatment. In this PRO part of the debate, we highlight the shortcomings of the PEXIVAS trial and stimulate further research paths, which in our eyes are necessary before abandoning PLEX from the therapeutic armamentarium.
      PubDate: Tue, 29 Dec 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa311
      Issue No: Vol. 36, No. 2 (2020)
       
  • Plasma exchange for the management of ANCA-associated vasculitis: the con
           position
    • Authors: Specks U; Fussner L, Cartin-Ceba R, et al.
      Pages: 231 - 236
      Abstract: Advances in the diagnosis and treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis have led to continued improvement in survival and prognosis over the course of the last 4 decades. Nevertheless, the most acute and severe disease manifestations, including severe kidney disease and alveolar hemorrhage, continue to be associated with increased early mortality from disease activity or treatment complications as well as risk for the development of end-stage kidney disease (ESKD), which in turn directly affects the overall prognosis of ANCA-associated vasculitis. Plasma exchange (PLEX) has long been proposed and used for these most severe disease manifestations under the assumption that its effects are swift and supported by our understanding of the pathogenic role of ANCA. Yet convincing evidence of a beneficial effect of PLEX in ANCA-associated vasculitis has been lacking, as early studies and small trials have generated conflicting results. The controversy regarding PLEX has been accentuated recently as the largest randomized controlled trial ever conducted in ANCA-associated vasculitis, the Plasma Exchange and Glucocorticoids in Severe ANCA-associated Vasculitis trial, which was specifically designed to evaluate the efficacy of PLEX in patients with severe renal disease or alveolar hemorrhage, failed to show a difference in the combined primary outcome measure of death or ESKD in patients who received PLEX versus those who did not. In light of these disappointing results, we herein review the currently available data on PLEX for ANCA-associated vasculitis and explain why we believe that these data no longer support the use of PLEX in ANCA-associated vasculitis.
      PubDate: Tue, 29 Dec 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa312
      Issue No: Vol. 36, No. 2 (2020)
       
  • Mutations in transcription factor CP2-like 1 may cause a novel syndrome
           with distal renal tubulopathy in humans
    • Authors: Klämbt V; Werth M, Onuchic-Whitford A, et al.
      Pages: 237 - 246
      Abstract: BackgroundAn underlying monogenic cause of early-onset chronic kidney disease (CKD) can be detected in ∼20% of individuals. For many etiologies of CKD manifesting before 25 years of age, >200 monogenic causative genes have been identified to date, leading to the elucidation of mechanisms of renal pathogenesis.MethodsIn 51 families with echogenic kidneys and CKD, we performed whole-exome sequencing to identify novel monogenic causes of CKD.ResultsWe discovered a homozygous truncating mutation in the transcription factor gene transcription factor CP2-like 1 (TFCP2L1) in an Arabic patient of consanguineous descent. The patient developed CKD by the age of 2 months and had episodes of severe hypochloremic, hyponatremic and hypokalemic alkalosis, seizures, developmental delay and hypotonia together with cataracts. We found that TFCP2L1 was localized throughout kidney development particularly in the distal nephron. Interestingly, TFCP2L1 induced the growth and development of renal tubules from rat mesenchymal cells. Conversely, the deletion of TFCP2L1 in mice was previously shown to lead to reduced expression of renal cell markers including ion transporters and cell identity proteins expressed in different segments of the distal nephron. TFCP2L1 localized to the nucleus in HEK293T cells only upon coexpression with its paralog upstream-binding protein 1 (UBP1). A TFCP2L1 mutant complementary DNA (cDNA) clone that represented the patient’s mutation failed to form homo- and heterodimers with UBP1, an essential step for its transcriptional activity.ConclusionHere, we identified a loss-of-function TFCP2L1 mutation as a potential novel cause of CKD in childhood accompanied by a salt-losing tubulopathy.
      PubDate: Fri, 23 Oct 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa215
      Issue No: Vol. 36, No. 2 (2020)
       
  • Novel in vitro assays to detect circulating permeability factor(s) in
           idiopathic focal segmental glomerulosclerosis
    • Authors: den Braanker D; Maas R, Deegens J, et al.
      Pages: 247 - 256
      Abstract: BackgroundMany patients with idiopathic focal segmental glomerulosclerosis (FSGS) develop recurrence of proteinuria after kidney transplantation (TX). Although several circulating permeability factors (CPFs) responsible for recurrence have been suggested, there is no consensus. To facilitate CPF identification and predict recurrence after TX, there is a need for robust methods that demonstrate the presence of CPFs.MethodsCultured human podocytes (hPods) and human and mouse glomerular endothelial cells (ciGEnC, mGEnC) were exposed to plasmas of FSGS patients with presumed CPFs, and of (disease) controls. A visual scoring assay and flow cytometry analysis of side scatter were used to measured changes in cellular granularity after exposure to plasma.ResultsNine out of 13 active disease plasmas of 10 FSGS patients with presumed CPFs induced granularity in hPod in a dose- and time-dependent manner. Corresponding remission plasmas induced no or less granularity in hPod. Similar results were obtained with ciGEnC and mGEnC, although induced granularity was less compared with hPod. Notably, foetal calf serum, healthy plasma and a remission plasma partially blocked FSGS plasma-induced hPod granularity.ConclusionsWe developed a novel assay in which active disease, presumably CPF-containing, FSGS plasmas induced granularity in cultured hPod. Our results may indicate the presence of CPF inhibitor(s) in healthy and remission plasma. We suggest the presence of a delicate balance between CPF and a CPF inhibitory factor, which is disturbed in patients with active disease. Our novel assays can be applied in future research to identify CPF and CPF inhibitors, and possibly to predict recurrence after TX.
      PubDate: Fri, 06 Nov 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa211
      Issue No: Vol. 36, No. 2 (2020)
       
  • Treprostinil, a prostacyclin analog, ameliorates renal
           ischemia–reperfusion injury: preclinical studies in a rat model of acute
           kidney injury
    • Authors: Ding M; Tolbert E, Birkenbach M, et al.
      Pages: 257 - 266
      Abstract: BackgroundRenal ischemia–reperfusion injury (IRI) is a major factor causing acute kidney injury (AKI). No pharmacological treatments for prevention or amelioration of I/R-induced renal injury are available. Here we investigate the protective effects of treprostinil, a prostacyclin analog, against renal IRI in vivo.MethodsMale Sprague Dawley rats were subjected to bilateral renal ischemia (45 min) followed by reperfusion for 1–168 h. Treprostinil (100 ng/kg/min) or placebo was administered subcutaneously for 18–24 h before ischemia.ResultsTreatment with treprostinil both significantly reduced peak elevation and accelerated the return to baseline levels for serum creatinine and blood urea nitrogen versus I/R-placebo animals following IRI. I/R-treprostinil animals exhibited reduced histopathological features of tubular epithelial injury versus I/R-placebo animals. IRI resulted in a marked induction of messenger RNA coding for kidney injury biomarkers, kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin and for pro-inflammatory cytokines chemokine (C-C motif) ligand 2, interleukin 1β, interleukin 6 and intracellular adhesion molecular 1 in animals treated with placebo only relative to sham controls. Upregulation of expression of all these genes was significantly suppressed by treprostinil. Treprostinil significantly suppressed the elevation in renal lipid peroxidation found in the I/R-placebo group at 1-h post-reperfusion. In addition, renal protein expression of cleaved poly(ADP-ribose) polymerase 1 and caspase-3, -8 and -9 in I/R-placebo animals was significantly inhibited by treprostinil.ConclusionsThis study demonstrates the efficacy of treprostinil in ameliorating I/R-induced AKI in rats by significantly improving renal function early post-reperfusion and by inhibiting renal inflammation and tubular epithelial apoptosis. Importantly, these data suggest that treprostinil has the potential to serve as a therapeutic agent to protect the kidney against IRI in vivo.
      PubDate: Fri, 06 Nov 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa236
      Issue No: Vol. 36, No. 2 (2020)
       
  • Types of erythropoiesis-stimulating agents and risk of end-stage kidney
           disease and death in patients with non-dialysis chronic kidney disease
    • Authors: Minutolo R; Garofalo C, Chiodini P, et al.
      Pages: 267 - 274
      Abstract: BackgroundDespite the widespread use of erythropoiesis-stimulating agents (ESAs) to treat anaemia, the risk of adverse outcomes associated with the use of different types of ESAs in non-dialysis chronic kidney disease (CKD) is poorly investigated.MethodsFrom a pooled cohort of four observational studies, we selected CKD patients receiving short-acting (epoetin α/β; n = 299) or long-acting ESAs (darbepoetin and methoxy polyethylene glycol-epoetin β; n = 403). The primary composite endpoint was end-stage kidney disease (ESKD; dialysis or transplantation) or all-cause death. Multivariable Cox models were used to estimate the relative risk of the primary endpoint between short- and long-acting ESA users.ResultsDuring follow-up [median 3.6 years (interquartile range 2.1–6.3)], the primary endpoint was registered in 401 patients [166 (72%) in the short-acting ESA group and 235 (58%) in the long-acting ESA group]. In the highest tertile of short-acting ESA dose, the adjusted risk of primary endpoint was 2-fold higher {hazard ratio [HR] 2.07 [95% confidence interval (CI) 1.37–3.12]} than in the lowest tertile, whereas it did not change across tertiles of dose for long-acting ESA patients. Furthermore, the comparison of ESA type in each tertile of ESA dose disclosed a significant difference only in the highest tertile, where the risk of the primary endpoint was significantly higher in patients receiving short-acting ESAs [HR 1.56 (95% CI 1.09–2.24); P = 0.016]. Results were confirmed when ESA dose was analysed as continuous variable with a significant difference in the primary endpoint between short- and long-acting ESAs for doses >105 IU/kg/week.ConclusionsAmong non-dialysis CKD patients, the use of a short-acting ESA may be associated with an increased risk of ESKD or death versus long-acting ESAs when higher ESA doses are prescribed.
      PubDate: Sun, 23 Aug 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa088
      Issue No: Vol. 36, No. 2 (2020)
       
  • Assisted peritoneal dialysis and transfer to haemodialysis: a
           cause-specific analysis with data from the RDPLF
    • Authors: Lanot A; Bechade C, Boyer A, et al.
      Pages: 330 - 339
      Abstract: BackgroundTechnique failure, defined as death or transfer to haemodialysis (HD), is a major concern in peritoneal dialysis (PD). Nurse-assisted PD is globally associated with a lower risk of transfer to HD. We aimed to evaluate the association between assisted PD and the risk of the different causes of transfer to HD.MethodsThis was a retrospective study using data from the French Language PD Registry of patients on incident PD from 2006 to 2015. The association between the use of assisted PD and the causes of transfer to HD was evaluated using survival analysis with competing events in unmatched and propensity score-matched cohorts.ResultsThe study included 11 093 incident PD patients treated in 123 French PD units. There were 4273 deaths, 3330 transfers to HD and 2210 renal transplantations. The causes of transfer to HD were inadequate dialysis (1283), infection (524), catheter-related problems (334), social issues (250), other causes linked to PD (422), other causes not linked to PD (481) and encapsulating peritoneal sclerosis (6). Nurse-assisted PD patients were older and more comorbid. Assistance by nurse was associated with a higher risk of death [cause-specific hazard ratio (cs-HR) 2.49, 95% confidence interval (CI) 2.26–2.74], but with a lower risk of transfer to HD [subdistributionHR (sd-HR) 0.68, 95% CI 0.62–0.76], especially due to inadequate dialysis (cs-HR 0.83, 95% CI 0.75–0).ConclusionsThe lower risk of transfer to HD associated with nurse assistance should encourage decision makers to launch reimbursement programmes in countries where it is not available.
      PubDate: Sun, 13 Dec 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa289
      Issue No: Vol. 36, No. 2 (2020)
       
  • Adverse gastrointestinal events with sodium polystyrene sulphonate and
           calcium polystyrene sulphonate use in dialysis patients: a nationwide
           registry study
    • Authors: Ferreira J; Couchoud C, Edet S, et al.
      Pages: 339 - 345
      Abstract: IntroductionSodium polystyrene sulphonate (SPS) and calcium polystyrene sulphonate (CPS) are commonly used cation-exchange resins for the treatment and control of hyperkalaemia. However, their use (particularly SPS) has been limited by reports of adverse gastrointestinal (GI) events. The safety of these compounds in patients undergoing dialysis requires larger investigation.AimsTo study the occurrence of adverse GI events (occlusion, perforation, thrombosis/ischaemia) in the periods of SPS or CPS exposition versus the periods without exposition in dialysis patients.MethodsDialysis patients were extracted from the French National Registry and merged with the French hospital discharge database (between 2006 and 2017). For our primary analysis, we used patients who had any claim of SPS use (n = 43 771). Time-varying Cox models, negative binomial regression and pre- versus post-treatment average treatment effects.ResultsThe mean age was 66 ± 15 years, 37% were female and 92% were undergoing haemodialysis. Over a 1-year follow-up, patients on periods with SPS (on-SPS) did not present an increased risk of adverse GI events versus the periods without SPS (off-SPS):  incidence rate (IR) (per 1000 person years) = 7.4 (6.4–8.7) versus 9.5 (8.1–11.0); adjusted hazard ratio (HR) (95% CI) = 0.81 (0.60–1.09), P = 0.17. Patients exposed to SPS did not experience a higher rate of adverse GI events in the year after SPS initiation versus the year before SPS initiation; P-value for parallel trend = 0.87. Patients on-CPS also did not show an increased risk of adverse GI events versus off-CPS: IR (per 1000 py) = 8.6 (5.1–11.9) versus 7.8 (5.1–11.9); adjusted HR (95% CI) = 0.76 (0.31–1.80), P = 0.52. The rates of adverse GI events in the periods on and off exposure were also similar over a follow-up of 5 years.ConclusionOur large, nationwide study shows that the incidence of adverse GI events in patients undergoing dialysis was low and that neither the use of SPS nor CPS was associated with increased GI events risk.
      PubDate: Sat, 28 Nov 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa229
      Issue No: Vol. 36, No. 2 (2020)
       
  • Evolution of body composition and wasting indicators by time of day of
           haemodialysis
    • Authors: Carrero J; Zawada A, Wolf M, et al.
      Pages: 346 - 354
      Abstract: BackgroundIt has been a long-standing clinical concern that haemodialysis (HD) patients on afternoon shifts (ASs) are more prone to protein-energy wasting (PEW) than those on morning shifts (MSs), as their dialysis scheme and post-dialysis symptoms may interfere with meal intake. We evaluated the effect of time of day of HD on the evolution of body composition changes and PEW surrogates.MethodsWe conducted a retrospective study among 9.963 incident HD patients treated in NephroCare centres (2011–16); data were routinely collected in the European Clinical Database. The course of multi-frequency bioimpedance determined lean and fat tissue indices (LTI and FTI) between patients in MSs/ASs over 2 years were compared with linear mixed models. Secondary PEW indicators were body mass index, albumin, creatinine index and normalized protein catabolic rate. Models included fixed (age, sex, vascular access and diabetes mellitus) and random effects (country and patient).ResultsMean baseline LTI and FTI were comparable between MSs (LTI: 12.5 ± 2.9 kg/m2 and FTI: 13.7 ± 6.0 kg/m2) and ASs (LTI: 12.4 ± 2.9 kg/m2 and FTI: 13.2 ± 6.1 kg/m2). During follow-up, LTI decreased and FTI increased similarly, with a mean absolute change (baseline to 24 months) of −0.3 kg/m2 for LTI and +1.0 kg/m2 for FTI. The course of these malnutrition indicators did not differ between dialysis shifts (P for interaction ≥0.10). We also did not observe differences between groups for secondary PEW indicators.ConclusionsThis study suggests that a dialysis shift in the morning or in the afternoon does not impact the long-term nutritional status of HD patients. Regardless of time of day of HD, patients progressively lose muscle mass and increase body fat.
      PubDate: Tue, 22 Dec 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa253
      Issue No: Vol. 36, No. 2 (2020)
       
  • Development and validation of a risk score for the prediction of
           cardiovascular disease in living donor kidney transplant recipients
    • Authors: Ueki K; Tsuchimoto A, Matsukuma Y, et al.
      Pages: 365 - 374
      Abstract: BackgroundCardiovascular disease (CVD) is a major cause of death in kidney transplant (KT) recipients. To improve their long-term survival, it is clinically important to estimate the risk of CVD after living donor KT via adequate pre-transplant CVD screening.MethodsA derivation cohort containing 331 KT recipients underwent living donor KT at Kyushu University Hospital from January 2006 to December 2012. A prediction model was retrospectively developed and risk scores were investigated via a Cox proportional hazards regression model. The discrimination and calibration capacities of the prediction model were estimated via the c-statistic and the Hosmer–Lemeshow goodness of fit test. External validation was estimated via the same statistical methods by applying the model to a validation cohort of 300 KT recipients who underwent living donor KT at Tokyo Women’s Medical University Hospital.ResultsIn the derivation cohort, 28 patients (8.5%) had CVD events during the observation period. Recipient age, CVD history, diabetic nephropathy, dialysis vintage, serum albumin and proteinuria at 12 months after KT were significant predictors of CVD. A prediction model consisting of integer risk scores demonstrated good discrimination (c-statistic 0.88) and goodness of fit (Hosmer–Lemeshow test P = 0.18). In a validation cohort, the model demonstrated moderate discrimination (c-statistic 0.77) and goodness of fit (Hosmer–Lemeshow test P = 0.15), suggesting external validity.ConclusionsThe above-described simple model for predicting CVD after living donor KT was accurate and useful in clinical situations.
      PubDate: Sat, 26 Dec 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa275
      Issue No: Vol. 36, No. 2 (2020)
       
  • Serial troponin measurements to monitor risk and response to endothelin A
           antagonism in chronic kidney disease
    • Authors: Anand A; Farrah T, Miller-Hodges E, et al.
      Pages: 375 - 377
      Abstract: Chronic kidney disease (CKD) is a global epidemic, but efforts to reduce its burden have been less effective than for other non-communicable diseases. Between 1990 and 2017, the global age-standardized mortality rate fell by 41.3% for chronic obstructive pulmonary disease, 30.4% for cardiovascular disease, 14.9% for cancer, but by only 2.8% for CKD [1]. Importantly, CKD is an independent risk factor for cardiovascular disease (CVD), which is its most common endpoint [2]. Indeed, in a recent analysis, almost 7% of global CVD burden was attributed to impaired kidney function [3]. Identifying cardiovascular risk early in CKD and assessing its response to treatments are key unmet clinical challenges.
      PubDate: Sun, 27 Sep 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa214
      Issue No: Vol. 36, No. 2 (2020)
       
  • Albuminuria in parents with type 2 diabetes is associated with age-related
           increase in low-density lipoprotein cholesterol and increased albuminuria
           in non-diabetic offspring
    • Authors: Bacci S; Tinti M, Rauseo A, et al.
      Pages: 378 - 379
      Abstract: Low-density lipoprotein cholesterol (LDLc), which progressively increases with age in the general population [1, 2], is a well-known risk factor for cardiovascular events (CVEs) [3]. In addition, LDLc plays a role in the development and progression of diabetic nephropathy [4, 5]. Some reports have shown that cholesterol-lowering treatment reduces urinary albumin excretion in patients with type 2 diabetes mellitus (T2DM) [6, 7], suggesting a potential causal relationship between cholesterol level and diabetic nephropathy. Both LDLc level and urinary albumin excretion are determined (at least in part) by genetic factors [8, 9] and their heritability could be closely interrelated.
      PubDate: Mon, 16 Nov 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa235
      Issue No: Vol. 36, No. 2 (2020)
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 18.206.177.17
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-